Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment

Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed Epstein-Barr virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hiroaki, Aoki, Hanako, Sugita, Yasumasa, Shimizu, Ryo, Kiko, Katsunari, Mochida, Hidetoshi, Suzuki, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675939/
https://www.ncbi.nlm.nih.gov/pubmed/28924126
http://dx.doi.org/10.2169/internalmedicine.8781-16
_version_ 1783276989321314304
author Tanaka, Hiroaki
Aoki, Hanako
Sugita, Yasumasa
Shimizu, Ryo
Kiko, Katsunari
Mochida, Hidetoshi
Suzuki, Yoshio
author_facet Tanaka, Hiroaki
Aoki, Hanako
Sugita, Yasumasa
Shimizu, Ryo
Kiko, Katsunari
Mochida, Hidetoshi
Suzuki, Yoshio
author_sort Tanaka, Hiroaki
collection PubMed
description Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed Epstein-Barr virus (EBV)-related primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) after mogamulizumab therapy. Our experience should alert physicians to the possibility of the development of EBV-related CNS DLBCL in patients treated for primary lymphoma and suggests that the anti-tumor immune effect of mogamulizumab is ineffective for the prophylaxis of EBV-related lymphomas.
format Online
Article
Text
id pubmed-5675939
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-56759392017-11-13 Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment Tanaka, Hiroaki Aoki, Hanako Sugita, Yasumasa Shimizu, Ryo Kiko, Katsunari Mochida, Hidetoshi Suzuki, Yoshio Intern Med Case Report Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed Epstein-Barr virus (EBV)-related primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) after mogamulizumab therapy. Our experience should alert physicians to the possibility of the development of EBV-related CNS DLBCL in patients treated for primary lymphoma and suggests that the anti-tumor immune effect of mogamulizumab is ineffective for the prophylaxis of EBV-related lymphomas. The Japanese Society of Internal Medicine 2017-09-15 2017-10-15 /pmc/articles/PMC5675939/ /pubmed/28924126 http://dx.doi.org/10.2169/internalmedicine.8781-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Tanaka, Hiroaki
Aoki, Hanako
Sugita, Yasumasa
Shimizu, Ryo
Kiko, Katsunari
Mochida, Hidetoshi
Suzuki, Yoshio
Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
title Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
title_full Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
title_fullStr Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
title_full_unstemmed Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
title_short Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment
title_sort development of epstein-barr virus-related primary diffuse large b-cell lymphoma of the central nervous system in a patient with peripheral t-cell lymphoma, not otherwise specified after mogamulizumab treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675939/
https://www.ncbi.nlm.nih.gov/pubmed/28924126
http://dx.doi.org/10.2169/internalmedicine.8781-16
work_keys_str_mv AT tanakahiroaki developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment
AT aokihanako developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment
AT sugitayasumasa developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment
AT shimizuryo developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment
AT kikokatsunari developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment
AT mochidahidetoshi developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment
AT suzukiyoshio developmentofepsteinbarrvirusrelatedprimarydiffuselargebcelllymphomaofthecentralnervoussysteminapatientwithperipheraltcelllymphomanototherwisespecifiedaftermogamulizumabtreatment

Ejemplares similares